X0306 4 2013-08-27 0 0001311596 Regado Biosciences Inc RGDO 0001435388 Clark B. Jefferson 120 MOUNTAIN VIEW BOULEVARD BASKING RIDGE NJ 07920 1 0 0 0 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 145411 A 164722 I See Footnote 7 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 87325 A 252047 I See Footnote 7 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 133067 A 385114 I See Footnote 7 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 321973 A 707087 I See Footnote 7 Common Stock, par value $0.001 per share 2013-08-27 4 C 0 48362 A 755449 I See Footnote 7 Common Stock, par value $0.001 per share 2013-08-27 4 P 0 359310 4.00 A 1114759 I See Footnote 8 Stock Option (right to buy) 4.00 2013-08-27 4 A 0 17964 0 A 2023-08-27 Common Stock, par value $0.001 per share 17964 17964 D Series A Preferred Stock 2013-08-27 4 C 0 2428367 0 D Common Stock, par value $0.001 per share 145411 0 I See Footnote 7 Series B Preferred Stock 2013-08-27 4 C 0 1458333 0 D Common Stock, par value $0.001 per share 87325 0 I See Footnote 7 Series C Preferred Stock 2013-08-27 4 C 0 2222222 0 D Common Stock, par value $0.001 per share 133067 0 I See Footnote 7 Series D Preferred Stock 2013-08-27 4 C 0 5376964 0 A Common Stock, par value $0.001 per share 321973 0 I See Footnote 7 Series E Preferred Stock 2013-08-27 4 C 0 807652 0 D Common Stock, par value $0.001 per share 48362 0 I See Footnote 7 100% of the shares underlying the option will vest on the one-year anniversary of the date of grant. The shares of Series A Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series A Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series B Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series C Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration. Except as noted in footnote 8 of this Form 4, the reportable securities are directly held by Aurora Ventures IV, LLC ("Aurora IV"). The Reporting Person is the manager of A.V. Management IV, L.L.C., the managing member of Aurora IV, and may be deemed to share voting and investment power. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. The reportable securities are directly held by Aurora Ventures V, L.P ("Aurora V"). The Reporting Person is the manager of A.V. Management V, L.L.C., the managing member of Aurora V, and may be deemed to share voting and investment power. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. /s/ B. Jefferson Clark by Christopher Courts, Attorney-in-Fact 2013-08-29